Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Legal Cannabis Product Sales Continues to Grow

FinancialBuzz.com
Posted on: 31 Jul 17

NEW YORK, July 31, 2017 /PRNewswire/ --

According to a report published by Hemp Business Journal, the total value of hemp products sold in the U.S. was $688 million in 2016 and the market is growing at a compound rate of 22 percent. Rapid growth in hemp CBD products continues to boost the market. Sales of CBD products are growing at a 53 percent AGR and reached $130 million in 2016. The report indicated that the Hemp CBD category was led by channel sales in natural and specialty products, smoke shops, and online verticals. Growing adoption of cannabis-based products by individual consumers is another factor that drives the growth of the market. Cannabis use medically is now legal in 29 states. ChineseInvestors.com, Inc. (OTC: CIIX), SinglePoint, Inc. (OTC: SING), Terra Tech Corp. (OTC: TRTC), Medical Marijuana, Inc. (OTC: MJNA), CV Sciences, Inc. (OTC: CVSI).

Sean Murphy, the Founder and Publisher of Hemp Business Journal, said: "Hemp Business Journal estimates the total retail value of all hemp products sold in the U.S. to be at least $688 million for 2016. We estimate the hemp industry will grow to $1.8 billion in sales by 2020, led by hemp food, body care, and CBD-based products. The data demonstrates the hemp industry is growing quickly at 22% five year CAGR and being led by food and body care products, with Hemp CBD products showing a 53% AGR."

ChineseInvestors.com, Inc. (OTCQB: CIIX) earlier this morning announced that, "Its wholly-owned subsidiary, ChineseHempOil.com, Inc., has established a Hemp Education Center in San Gabriel, California. The Company's club-style Hemp Education Center is at the center of San Gabriel's lively and growing Chinese-speaking community. Through its education center, ChineseHempOil.com, Inc. aims to provide valuable information to those that want to learn more about the potential health benefits of non-industrial hemp and hemp-derived CBD, while also increasing general awareness about non-industrial hemp which has roots in ancient Chinese medicine."

"I am delighted about the possibilities of our new Hemp Education Center," says Warren Wang, Founder and CEO of CIIX. "In recognition of the unprecedented opportunities in the legal non-industrial hemp industry, CIIX expanded its business to capitalize on the growing demand for hemp health products. Our new club-style Hemp Education Center will build awareness of the hemp industry and our brand while laying the groundwork for ChineseHempOil.com to be recognized as the premiere name in hemp products within the Chinese-speaking market.

Events and activities offered at the Hemp Education Center will work in conjunction with CIIX's local advertising presence as part of its broader strategy to solidify brand recognition and help spread the word about the Company's hemp products and hemp-derived CBD products.

We expect that community-centered education and outreach about the potential benefits of hemp and hemp-derived CBD will successfully drive demand for our products and raise the visibility of our unique services and products, especially among the Chinese-speaking population," concludes Wang.

SinglePoint, Inc. (OTC: SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base. SinglePoint, Inc. announced on June 27th, that its recently acquired DIGS Hydro subsidiary has received a major purchase order from Premier Biomedical. DIGS Hydro has received the initial payment with final payment due on delivery. Based on recent discussions between the parties, Premier Biomedical plans to continue to order its supplies from DIGS Hydro, a provider of a variety of supplies and services specifically to the cannabis industry.

Terra Tech Corp. (OTCQX: TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Blüm's retail and medical cannabis facilities provide the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions as well as premium cannabis to the adult-use market in Nevada. The company announced on July 20th, that it is ramping up its marketing campaign for its subsidiary, Edible Garden®, a provider of fresh, locally grown herbs and leafy greens nationwide. As part of the Company's new marketing campaign, Edible Garden has secured a feature slot for its nutritionally-enhanced SUPERLEAF™ salad on the television show 'Plant Based by Nafsika', on A&E's FYI Channel at 7:30 am ET on July 26th, 2017.

Medical Marijuana, Inc. (OTC: MJNA) has a mission to be the premier cannabis and hemp industry innovators, leveraging their team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. On July 27th, Medical Marijuana, Inc. announced that its major investment AXIM Biotechnologies, Inc. has entered into a Services Agreement with an Israel-based contract research organization to begin a clinical proof of concept study (POC) with its cannabidiol and Gabapentin chewing gum product to treat restless leg syndrome in patients. 

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. On July 20th, CV Sciences, Inc. highlighted a recent clinical study using pharmaceutical grade cannabidiol which suggests that CBD may be effective in blunting the rise in blood pressure associated with stress. A June 2017 report published in the Journal of Clinical Investigation Insight stated, "A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study."

Please Sign Up Now at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. 'The Latest Buzz in Financial News'

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com expects to be compensated three thousand dollars for financial news dissemination and PR services by chineseinvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, and quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .

For further information:
info@financialbuzz.com
+1-877-601-1879

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 31/07/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.